BTK Inhibitor Reduces New Lesions in Relapsing Multiple Sclerosis
Tolebrutinib may hold promise for progressive MS, too by Judy George, Senior Staff Writer, MedPage Today September 3, 2021 Tolebrutinib, a…
BTK Inhibitor Fenebrutinib Aims to Tackle Progressive MS in FENtrepid Trial
August 20, 2021 – Marco Meglio NeurologyLive, August 2021, Volume 4, Issue 4 The agent’s safety profile has been studied in…
Stuart Schlossman
6-Week Dosing of Natalizumab Effective, May Reduce PML Risk
August 3, 2021 – Abby Reinhard Efficacy data from a trial examining extended dosing adds to real-world data that demonstrates…
Stuart Schlossman
Trial Will Test Mavenclad for Advanced Progressive MS
After some delays due to the COVID-19 pandemic, the Phase 2/3 clinical trial evaluating whether Mavenclad (cladribine) can slow hand and arm…
Stuart Schlossman
Learn about PONVORY™ (ponesimod), a prescription medicine that is used to treat relapsing forms of multiple sclerosis
PONVORY™ is a prescription medicine that is used to treat relapsing forms of multiple sclerosis, to include clinically isolated…
Stuart Schlossman
Could BTK Inhibitors Be the Next Big MS Treatment?
by Ed Tobias | July 30, 2021 – The MS Wire Is orelabrutinib one of the next big MS therapies? Biogen…
Stuart Schlossman
Gilenya Started Earlier in RRMS Disease Course in Recent Years
By Marisa Wexler MS on Jul 26, 2021 People with relapsing-remitting multiple sclerosis (RRMS) have switched to treatment with Gilenya (fingolimod) at an earlier…
Stuart Schlossman
At-home Tysabri Infusions Appear as Safe, Effective as Those at Clinics
by Forest Ray PhD | July 26, 2021 Tysabri (natalizumab) infusions given in the home to people with relapsing-remitting multiple sclerosis (RRMS) save money and are…
Stuart Schlossman
First-Line Treatment Considerations in RRMS
The NeurologyLive Insights series, “Use of High-Efficacy Therapies for Treatment of Relapsing Multiple Sclerosis,” features Enrique Alvarez, MD, PhD,…
Stuart Schlossman
Relapsing MS Patients May Fare Better on Zeposia Than Aubagio
Treatment with Zeposia (ozanimod) significantly reduces the risk of relapse, decreases the proportion of patients experiencing a relapse, and has a better…
Stuart Schlossman
